Literature DB >> 23850146

No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women.

Tsogzolmaa Dorjgochoo1, Ying Zheng, Yu-Tang Gao, Xiangyu Ma, Jirong Long, Pingping Bao, Ben Zhang, Wanqing Wen, Wei Lu, Wei Zheng, Xiao Ou Shu, Alicia Beeghly-Fadiel.   

Abstract

BACKGROUND: Angiogenesis and inflammation are implicated in breast cancer prognosis; however, the role of individual germline variation in related genes is unknown.
METHODS: A two-stage candidate pathway association study was conducted among 6983 Chinese women. Stage 1 included 2884 women followed for a median of 5.7 years; Stage 2 included 4099 women followed for a median of 4.0 years. Cox proportional hazards regression was used to estimate the effects of genetic variants on disease-free survival (DFS) and overall survival (OS).
RESULTS: Stage 1 included genotyping of 506 variants in 22 genes; analysis was conducted for 370 common variants. Nominally significant associations with DFS and/or OS were found for 20 loci in ten genes in Stage 1; variants in 19 loci were successfully genotyped and evaluated in Stage 2. In analyses of both study stages combined, nominally significant associations were found for nine variants in seven genes; none of these associations surpassed a significance threshold level corrected for the total number of variants evaluated in this study.
CONCLUSIONS: No association with survival was found for 370 common variants in 22 angiogenesis and inflammation pathway genes among Chinese women with breast cancer. IMPACT: Our data do not support a large role for common genetic variation in 22 genes in breast cancer prognosis; research on angiogenesis and inflammation genes should focus on common variation in other genes, rare host variants, or tumor alterations.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis genes; Breast cancer survival; CCL2; CCL5; CCR2; COL18A1; Chinese women; DFS; DNA; ER; FGFR4; FLT1; Genetic variants; HER2; HIF1A; HPGD; IL10; IL1B; IL6; Inflammation pathway genes; KDR; MAF; MMP1; MMP13; MMP2; MMP3; MMP7; MMP9; OS; PLAU; POSTN; PR; PTGES; PTGIS; PTGS2; SBCS; SBCSS; SERPINE1; SWHS; Shanghai Breast Cancer Study; Shanghai Breast Cancer Survival Study; Shanghai Women's Health Study; TGFB1; THBS1; VEGFA; chemokine (C-C motif) ligand 2; chemokine (C-C motif) ligand 5; chemokine (C-C motif) receptor 2; collagen, type XVIII, alpha 1; deoxyribonucleic acid; disease-free survival; estrogen receptor; fibroblast growth factor receptor 4; fms-related tyrosine kinase 1; human epidermal growth factor receptor 2; hydroxyprostaglandin dehydrogenase; hypoxia inducible factor 1, alpha subunit; interleukin 1, beta; interleukin 10; interleukin 6; kb; kilobase; kinase insert domain receptor; matrix metallopeptidase 1; matrix metallopeptidase 13; matrix metallopeptidase 2; matrix metallopeptidase 3; matrix metallopeptidase 7; matrix metallopeptidase 9; minor allele frequency; overall survival; periostin, osteoblast specific factor; plasminogen activator, urokinase; progesterone receptor; prostaglandin E synthase; prostaglandin I2 synthase; prostaglandin-endoperoxide synthase 2; serpin peptidase inhibitor, clade E, member 1 (previously known as PAI1); thrombospondin 1; transforming growth factor, beta 1; vascular endothelial growth factor A

Mesh:

Year:  2013        PMID: 23850146      PMCID: PMC4064366          DOI: 10.1016/j.canep.2013.06.005

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  14 in total

1.  Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.

Authors:  Haixin Lei; Kari Hemminki; Andrea Altieri; Robert Johansson; Kerstin Enquist; Göran Hallmans; Per Lenner; Asta Försti
Journal:  Breast Cancer Res Treat       Date:  2006-10-11       Impact factor: 4.872

2.  Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.

Authors:  Asta Försti; Qianren Jin; Andrea Altieri; Robert Johansson; Kerstin Wagner; Kerstin Enquist; Ewa Grzybowska; Jolanta Pamula; Wioletta Pekala; Göran Hallmans; Per Lenner; Kari Hemminki
Journal:  Breast Cancer Res Treat       Date:  2006-06-29       Impact factor: 4.872

3.  Soy food intake and breast cancer survival.

Authors:  Xiao Ou Shu; Ying Zheng; Hui Cai; Kai Gu; Zhi Chen; Wei Zheng; Wei Lu
Journal:  JAMA       Date:  2009-12-09       Impact factor: 56.272

4.  Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.

Authors:  Else Maae; Rikke Fredslund Andersen; Karina Dahl Steffensen; Erik Hugger Jakobsen; Ivan Brandslund; Flemming Brandt Sørensen; Anders Jakobsen
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

5.  The Shanghai Women's Health Study: rationale, study design, and baseline characteristics.

Authors:  Wei Zheng; Wong-Ho Chow; Gong Yang; Fan Jin; Nathaniel Rothman; Aaron Blair; Hong-Lan Li; Wanqing Wen; Bu-Tian Ji; Qi Li; Xiao-Ou Shu; Yu-Tang Gao
Journal:  Am J Epidemiol       Date:  2005-10-19       Impact factor: 4.897

6.  Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.

Authors:  Wei Zheng; Jirong Long; Yu-Tang Gao; Chun Li; Ying Zheng; Yong-Bin Xiang; Wanqing Wen; Shawn Levy; Sandra L Deming; Jonathan L Haines; Kai Gu; Alecia Malin Fair; Qiuyin Cai; Wei Lu; Xiao-Ou Shu
Journal:  Nat Genet       Date:  2009-02-15       Impact factor: 38.330

Review 7.  Breast cancer: the role of angiogenesis and antiangiogenic therapy.

Authors:  Kathy D Miller; Carrie L Dul
Journal:  Hematol Oncol Clin North Am       Date:  2004-10       Impact factor: 3.722

8.  Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.

Authors:  K C Smith; A C Bateman; H M Fussell; W M Howell
Journal:  Eur J Immunogenet       Date:  2004-08

9.  Association of interleukin-10 gene variation with breast cancer prognosis.

Authors:  Armin Gerger; Wilfried Renner; Tanja Langsenlehner; Günter Hofmann; Gudrun Knechtel; Joanna Szkandera; Hellmut Samonigg; Peter Krippl; Uwe Langsenlehner
Journal:  Breast Cancer Res Treat       Date:  2009-05-13       Impact factor: 4.872

Review 10.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.

Authors:  David G DeNardo; Lisa M Coussens
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  4 in total

1.  Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.

Authors:  Mitsukuni Suenaga; Sebastian Stintzing; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Satoshi Okazaki; Martin D Berger; Yuji Miyamoto; Marta Schirripa; Shivani Soni; Afsaneh Barzi; Volker Heinemann; Heinz-Josef Lenz
Journal:  Eur J Cancer       Date:  2018-12-14       Impact factor: 9.162

2.  Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.

Authors:  Hayra de Andrade Vieira-Monteiro; Daniely Regina Freitas-Alves; Marcelo Sobral-Leite; João Marcos de Azevedo Delou; Sheyla Maria Torres Goulart-Citrangulo; Camila Telles do Nascimento; Thales Nascimento E Castro; Sérgio Koifman; Jamila Alessandra Perini; Rosane Vianna-Jorge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

Review 3.  The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Authors:  Yahya I Elshimali; Husseina Khaddour; Marianna Sarkissyan; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

4.  Genetic variants in genes related to inflammation, apoptosis and autophagy in breast cancer risk.

Authors:  Johanna M Schuetz; Anne Grundy; Derrick G Lee; Agnes S Lai; Lindsay C Kobayashi; Harriet Richardson; Jirong Long; Wei Zheng; Kristan J Aronson; John J Spinelli; Angela R Brooks-Wilson
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.